| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.
|
J Clin Oncol
|
2008
|
5.46
|
|
2
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
J Clin Oncol
|
2008
|
5.04
|
|
3
|
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
|
Lancet Oncol
|
2009
|
3.21
|
|
4
|
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.
|
J Clin Oncol
|
2010
|
2.41
|
|
5
|
Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence.
|
Clin Cancer Res
|
2010
|
2.11
|
|
6
|
Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing.
|
Int J Radiat Oncol Biol Phys
|
2004
|
2.00
|
|
7
|
Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.31
|
|
8
|
A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.
|
Thyroid
|
2010
|
1.26
|
|
9
|
HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans.
|
Head Neck
|
2010
|
1.23
|
|
10
|
Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status.
|
Head Neck
|
2012
|
1.18
|
|
11
|
Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6.
|
Clin Cancer Res
|
2013
|
0.98
|
|
12
|
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
|
Clin Lung Cancer
|
2010
|
0.98
|
|
13
|
Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution.
|
Skull Base
|
2010
|
0.96
|
|
14
|
Outcomes evaluation of a weekly nurse practitioner-managed symptom management clinic for patients with head and neck cancer treated with chemoradiotherapy.
|
Oncol Nurs Forum
|
2013
|
0.94
|
|
15
|
Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
|
J Clin Endocrinol Metab
|
2006
|
0.94
|
|
16
|
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
|
Head Neck
|
2007
|
0.94
|
|
17
|
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.93
|
|
18
|
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.93
|
|
19
|
High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma.
|
Transl Oncol
|
2010
|
0.92
|
|
20
|
Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.
|
Invest New Drugs
|
2009
|
0.88
|
|
21
|
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
|
Horm Cancer
|
2014
|
0.87
|
|
22
|
Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
|
Head Neck
|
2014
|
0.87
|
|
23
|
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
|
Head Neck
|
2012
|
0.87
|
|
24
|
Trends in imaging after diagnosis of thyroid cancer.
|
Cancer
|
2015
|
0.86
|
|
25
|
Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer.
|
Radiother Oncol
|
2005
|
0.86
|
|
26
|
Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma.
|
Endocr Pract
|
2011
|
0.85
|
|
27
|
Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer.
|
Head Neck
|
2012
|
0.85
|
|
28
|
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
|
Cancer
|
2007
|
0.84
|
|
29
|
Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: are we changing life expectancy?
|
Laryngoscope
|
2012
|
0.84
|
|
30
|
Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.
|
Head Neck
|
2013
|
0.83
|
|
31
|
Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.
|
JAMA Ophthalmol
|
2013
|
0.82
|
|
32
|
Conditional survival in patients with thyroid cancer.
|
Thyroid
|
2014
|
0.82
|
|
33
|
Human papillomavirus-related oropharyngeal cancer: HPV and p16 status in the recurrent versus parent tumor.
|
Head Neck
|
2014
|
0.82
|
|
34
|
Chemoselection: a paradigm for optimization of organ preservation in locally advanced larynx cancer.
|
Expert Rev Anticancer Ther
|
2013
|
0.80
|
|
35
|
Chemotherapy alone for organ preservation in advanced laryngeal cancer.
|
Head Neck
|
2010
|
0.79
|
|
36
|
Osteocutaneous free tissue transplantation for mandibular osteoradionecrosis.
|
J Reconstr Microsurg
|
2012
|
0.78
|
|
37
|
Head and neck squamous cell carcinoma in pregnant women.
|
Head Neck
|
2012
|
0.78
|
|
38
|
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
|
J Thorac Oncol
|
2008
|
0.78
|
|
39
|
Use of warfarin in the patient with cancer.
|
J Support Oncol
|
2007
|
0.77
|
|
40
|
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
|
Head Neck
|
2014
|
0.77
|
|
41
|
Association Between Multimodality Neck Treatment and Work and Leisure Impairment: A Disease-Specific Measure to Assess Both Impairment and Rehabilitation After Neck Dissection.
|
JAMA Otolaryngol Head Neck Surg
|
2015
|
0.76
|
|
42
|
Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes.
|
J Pediatr Endocrinol Metab
|
2014
|
0.75
|
|
43
|
Axitinib in the Treatment of Head and Neck Malignancies.
|
Curr Clin Pharmacol
|
2016
|
0.75
|